Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-704-4040
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$41.37 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable
Harrow Health (NASDAQ:HROW) Frequently Asked Questions
What is Harrow Health's stock symbol?
Harrow Health trades on the NASDAQ under the ticker symbol "HROW."
How were Harrow Health's earnings last quarter?
Harrow Health (NASDAQ:HROW) released its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.27. The business had revenue of $12.76 million for the quarter, compared to analysts' expectations of $13.31 million. Harrow Health had a return on equity of 25.96% and a net margin of 31.32%. View Harrow Health's Earnings History.
When is Harrow Health's next earnings date?
What price target have analysts set for HROW?
1 equities research analysts have issued 1-year price targets for Harrow Health's stock. Their forecasts range from $15.00 to $15.00. On average, they expect Harrow Health's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 113.7% from the stock's current price. View Analyst Price Targets for Harrow Health.
What is the consensus analysts' recommendation for Harrow Health?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harrow Health.
Has Harrow Health been receiving favorable news coverage?
News coverage about HROW stock has trended very negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Harrow Health earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Harrow Health.
Who are some of Harrow Health's key competitors?
Some companies that are related to Harrow Health include Collegium Pharmaceutical (COLL), Akero Therapeutics (AKRO), Emisphere Technologies (EMIS), TherapeuticsMD (TXMD), DiaMedica Therapeutics (DMCAF), Flexion Therapeutics (FLXN), Frequency Therapeutics (FREQ), Omeros (OMER), Cara Therapeutics (CARA), Vectura Group (VEGPF), Urogen Pharma (URGN), AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF) and MacroGenics (MGNX).
What other stocks do shareholders of Harrow Health own?
Who are Harrow Health's key executives?
Harrow Health's management team includes the folowing people:
- Mr. Mark L. Baum, Founder, CEO & Director (Age 46)
- Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 37)
- Mr. John P. Saharek, Chief Commercial Officer (Age 59)
- Mr. David Moufarrège, VP of Technology
- Mr. Pramod Sharma Ph.D., VP of Quality
Who are Harrow Health's major shareholders?
Which institutional investors are selling Harrow Health stock?
Which institutional investors are buying Harrow Health stock?
How do I buy shares of Harrow Health?
Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Harrow Health's stock price today?
One share of HROW stock can currently be purchased for approximately $7.02.
How big of a company is Harrow Health?
Harrow Health has a market capitalization of $176.69 million and generates $41.37 million in revenue each year. The company earns $14.63 million in net income (profit) each year or $0.61 on an earnings per share basis. View Additional Information About Harrow Health.
What is Harrow Health's official website?
How can I contact Harrow Health?
Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company can be reached via phone at 858-704-4040 or via email at [email protected]
MarketBeat Community Rating for Harrow Health (NASDAQ HROW)
MarketBeat's community ratings are surveys of what our community members think about Harrow Health and other stocks. Vote "Outperform" if you believe HROW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HROW will underperform the S&P 500 over the long term. You may vote once every thirty days.
